
Understand how clinicians assess low testosterone symptoms using guideline thresholds, repeat testing and a review of sleep, health and medicines.

Low testosterone means a low concentration of testosterone in the blood. Male hypogonadism is a clinical diagnosis that requires compatible symptoms or signs together with consistently low testosterone. The European Association of Urology (EAU) guideline makes both parts necessary when assessing possible testosterone deficiency.
This article is for informational purposes only and is not medical advice. A qualified clinician should interpret personal symptoms and laboratory results. Decisions about further testing or treatment require an individual medical assessment.
The clinical numbers that matter here are guideline thresholds for investigating testosterone deficiency. They are not the boundaries of one universal normal range. The EAU framework and the Endocrine Society framework use different lower thresholds, so a result needs the context of the guidance being applied.
Biologically, these values describe the concentration of testosterone measured in blood. Clinically, they help assess whether a hormonal finding fits a man's symptoms and signs. They do not measure how much of his fatigue or reduced sexual interest is attributable to testosterone.
The EAU identifies 12 nmol/L (3.5 ng/mL) as a reliable threshold within its framework for late-onset hypogonadism. That framework also requires compatible symptoms or signs and confirmation of low testosterone under suitable testing conditions.
The useful question is therefore not simply whether a result falls below that value. It is whether the measurement and the clinical picture meet the same diagnostic framework.
A 2026 article in Clinical Chemistry summarized the Endocrine Society's 2018 guideline. It reported a morning total testosterone threshold of less than 264 ng/dL (9.2 nmol/L) alongside relevant clinical circumstances.
These thresholds should stay attached to their respective guidelines. They should not be combined into a new range or treated as interchangeable cutoffs. When discussing a report, identifying the framework and the units is more useful than comparing an isolated number with a threshold found elsewhere.
The EAU recommends measuring total testosterone between 07:00 and 10:00 while fasting and using a reliable laboratory assay. Its diagnostic approach requires low morning testosterone confirmed on at least two separate occasions.
Testing conditions and confirmation are part of interpreting the result, not administrative details. A clinician can explain whether an existing measurement meets those conditions and how confirmation should be arranged. Our guide to building a reliable assessment from symptoms and repeat measurements explains this distinction further.
The EAU recommends considering sex hormone-binding globulin, or SHBG, and calculated free testosterone when indicated. A 2026 review in Nature Reviews Urology also describes their usefulness when total testosterone is borderline or does not align with the symptoms.
These measurements add context to the assessment rather than replacing it. The relevant discussion is whether they would clarify an uncertain result in the particular clinical setting. Understanding how total and free testosterone fit into the same assessment can make that conversation easier to follow.
Symptoms differ in how strongly they point toward possible testosterone deficiency. The EAU identifies several sexual symptoms as more specific features associated with late-onset hypogonadism:
“More specific” does not mean diagnostic. These symptoms warrant consideration alongside blood testing and the broader health history. They are not a checklist that confirms hypogonadism when enough boxes are marked.
Fatigue and low mood can occur with testosterone deficiency, but they have several possible explanations. A clinical review of testosterone deficiency lists sleep apnoea and anaemia among alternative explanations for fatigue. It also includes hypothyroidism and depression.
The same review identifies depression and relationship factors as possible explanations for reduced libido. This matters because even a sexual symptom needs context. Its presence does not remove the need to consider other contributors.
For an adult man who feels tired and less interested in sex, the clinical task is to assess both concerns rather than force them into a single explanation. Sleep and mental health may be relevant to the symptom history. Testosterone testing addresses the separate question of whether biochemical evidence of deficiency is also present.
The research supports describing what has changed rather than arriving with only a label such as “low T.” It is useful to distinguish reduced desire from erection difficulties and to mention changes in spontaneous or morning erections. Fatigue and low mood should also be described without assuming their cause.
A clear account might identify which sexual symptoms are present and which broader concerns prompted the appointment. This gives the clinician more useful information than a general statement that every symptom must be hormonal. Our explanation of why symptoms need clinical and laboratory context develops that approach.
A clinical review lists several factors that clinicians may investigate when evaluating secondary or functional hypogonadism. Some may affect testosterone production. Others may also contribute to the symptoms that brought a man to care.
Their presence does not establish the cause of an individual's symptoms or test result. They are topics for assessment rather than ready-made explanations.
The review identifies the following areas:
This list supports a broader consultation, not a self-diagnosis exercise. Sleep concerns and known medical conditions are worth mentioning. Weight concerns and medicine use also give the clinician context for deciding what further assessment is appropriate.
The EAU recommends addressing relevant underlying conditions before testosterone therapy where appropriate. It also recommends withdrawing medicines that can impair testosterone production where possible. Any medication change belongs with the prescribing clinician and should not be made independently because of an article or laboratory result.
For men with hypogonadism who are overweight or obese, the EAU recommends lifestyle improvement and weight reduction. This is a guideline recommendation within clinical care. It is not a promise that changing weight will resolve every case of testosterone deficiency.
The Nature Reviews Urology review likewise describes evaluation of the cause as part of the clinical assessment. Confirming a hormonal finding and understanding its possible contributors are distinct tasks. Treatment decisions come after that assessment rather than replacing it.
A useful consultation therefore addresses the symptoms that need explanation and the circumstances surrounding the blood result. It also considers whether other conditions or medicines need attention before a treatment discussion. Knowing what a medical evaluation may cover can help keep those questions organised.
Ask your physician: “Which symptoms suggest testosterone deficiency in my case? Which guideline threshold applies to my result? Does it need repeat testing or clarification with SHBG and calculated free testosterone? Which sleep, health or medicine factors should we assess before discussing treatment?”
Overlapping fatigue and sexual symptoms call for careful explanation rather than a quick hormone label, which is the boundary Testostra maintains in its educational coverage. Its articles connect symptom uncertainty with the meaning of testosterone tests so readers have clearer language for discussing possible causes with a clinician.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra